VP3.15 dihydrobromide
Modify Date: 2024-01-09 15:27:34
VP3.15 dihydrobromide structure
|
Common Name | VP3.15 dihydrobromide | ||
|---|---|---|---|---|
| CAS Number | 1281681-33-1 | Molecular Weight | 528.30 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H24Br2N4OS | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of VP3.15 dihydrobromideVP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS)[1]. |
| Name | VP3.15 dihydrobromide |
|---|
| Description | VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS)[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.59 μM (PDE7), 0.88 μM (GSK-3)[1] |
| References |
| Molecular Formula | C20H24Br2N4OS |
|---|---|
| Molecular Weight | 528.30 |